YourEncore Insights - Life Sciences

State of the Industry: U.S. Regulatory Policy Improvements (Ep. 19 of The Pharmcast)

The Frontiers of Rare Disease Development: Advances in Regulatory Science with Dr. Tim Franson (Ep. 18 of The Pharmcast)

YourEncore Announces Addition of Michelle DeJonge and Dr. James Wood as Strategic Advisors for Medical Devices & Diagnostics Practice

Welcome to the Real World: A Reality Check for Digital Health with Dr. Ron Razmi (Ep. 17 of The Pharmcast)

7 Best Practices in Biologics Launch Communications (Ep. 16 of The Pharmcast)

The Future is Here: Using Big Data and Artificial Intelligence in Oncology (Ep. 15 of The Pharmcast)

Working with the FDA: Developing a Regulatory Strategy That Works (Ep. 14 of The Pharmcast)

Riding the Policy Roller Coaster in 2017: A Policy Update with Dr. Tim Franson (Ep. 13 of The Pharmcast)

Executive Briefing: EU Medical Device Regulation | 5 Ways EU MDR Will Impact Your Business [White Paper]

NDA Mistakes to Avoid: An Interview with Dr. Joseph Lamendola (Ep. 12 on The Pharmcast)

Medtech Valuation Killers: 10 Regulatory & Commercialization Traps to Avoid (Ep. 11 on The Pharmcast)

Patient Engagement: Putting Rare Disease Patients First (Ep. 10 on The Pharmcast)

No Surprises: Improving Medical Devices Due Diligence (Ep. 9 on The Pharmcast)

FDA 483 Responses: Avoiding Common Pitfalls and Deficiencies (Ep. 8 on The Pharmcast)

Bioethics in Biopharma: Lessons on Safety, Big Data and Bioethics from Dr. Don Therasse  (Ep. 7 on The Pharmcast)

From Big Pharma to Biotech C-Suite: Industry and Career Insights from Dr. June Almenoff (Ep. 6 on The Pharmcast)

Holiday Wish-Lists and Watch-Outs From Regulatory Leaders (Ep. 5 on The Pharmcast)

Billion Dollar Bets: Lessons on Innovation from a BMS Chief Scientific Officer, Dr. Elliott Sigal (Ep. 4 on The Pharmcast)

9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)

Leading the Bristol-Myers Squibb Transformation (Part 2) (Ep. 2 of The Pharmcast)

Leading the Bristol-Myers Squibb Transformation (Part 1) (Ep. 1 of The Pharmcast)

Navigating Drug-Device Combination Product Approval

Considering Biosimilars – 3 Key Areas to Assess in Your Strategy

Pharm-ers Almanac 2016: The Butterfly Effect

Are You Ready for EU MDR?

Drug Pricing – What’s the Answer to High Cost Off-Patent Medicines?

FDA 483 Response: Four Tips to Avoid a Warning Letter

Embracing Satan's PDUFA

Real World Evidence: Times They Are a (Slowly) Changin'

If Brexit, Whither EMA?

Getting Real World About Outcomes Data

[Watch] No Surprises: Improving Medical Devices Due Diligence

[Recording] EU Medical Device Regulation Presentation

Alternative Regulatory Pathways for Rare Disease: Breaking the ICE

Transparency Isn't a One-Way Proposition

FDA Gets Out In Front on Single Source Problem

Understanding and Maximizing Interactions with the Califf FDA

Roundtable: Driving Down Healthcare Costs

FDA Advisory Committee Mistakes to Avoid

FDA's Abuse-Deterrent Commissioner

From Snake Oil to Fish Oil: The Need for a New Approach to Off-Label Communication

A Biotech’s Guide to FDA’s 2016 Agenda

Regulatory R.A.N.T. - Biomarkers, Pediatrics, Benefit-Risk - Oh my!

FDA and NBCDs: Do Not Pass GAO

YourEncore Insights Greatest Hits of 2015

6 Must-Ask Questions Before Adding New Biomarkers to Your Clinical Trial Protocols

Transparency vs. Smoke and Mirrors: Clinical Trials Debate

Social Media & Postmarketing Surveillance - Signal vs. Noise

BioMarin Advisory Committee Outcome - Canary in the Coal Mine?

Regulatory Convergence & Divergence:  3 Possible Monkey Wrenches in Pharmaceutical Development Planning

Biosimilar Name Game:  The Brewing FTC & FDA Debate

Dr. Joseph Lamendola Fails Retirement:  Joins YourEncore as SVP of Regulatory Practice

Signs the FDA Dislikes Your Development Plan:  Ignore at Your Risk

Five Ways to Hasten Biomarker Development

Four New Drug Application (NDA) Mistakes to Avoid

FDA Communications Best Practices: Transparency

Expanding Expanded Access

The Patient Voice in 21st Century (Rare Disease) Drug Development

The FDA’s Quality Revolution

Top 10 Regulatory Issues for Today’s Drug Developers

All Things Regulatory: Is Bad Data Behind Pharma’s Negative Image?

All Things Regulatory: Back to the Future? Not Likely for FDA Approvals

All Things Regulatory: Pharma Trends

Dr. Stephen P. Spielberg Joins Regulatory Practice

All Things Regulatory: Introducing Our Experts

Video: YourEncore & EY Alliance - Better Together

Minnie Baylor-Henry Joins Regulatory Practice

Video: Get to Know YourEncore

Regulatory R.A.N.T. Highlights PDUFA

YourEncore Adds Mike Lewis As Chief Sales & Marketing Officer

The Pharm-er's Almanac - 10 Pharma Trends to Navigate Now

Rethink Retirement with Harry Coleman

YourEncore Assembles Regulatory Experts

YourEncore and ACRES Partner

YourEncore at DIA 2015

IFF Appoints Dr. Shekhar Mitra

Awesome Jobs When Over 50

Leigh Ann Pagnard, V.P. of Operations

Managing Contract Regulatory Resources

Growth of Free Agent Workforce